LeMaitre Vascular Resultados de beneficios anteriores

Pasado controles de criterios 5/6

LeMaitre Vascular ha aumentado sus beneficios a una tasa media anual de 6.3%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 13.5% anual. Los ingresos han ido creciendo a una tasa media de 12% al año. La rentabilidad financiera de LeMaitre Vascular es de 10.1%, y sus márgenes netos son de 15.6%.

Información clave

8.7%

Tasa de crecimiento de los beneficios

5.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	12.2%
Rentabilidad financiera	11.0%
Margen neto	17.0%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

Oct 27

Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Oct 11

Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

Aug 30

The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Jul 06

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

May 20

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Mar 12

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Oct 23

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Oct 05

LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital

Sep 13

LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers

Sep 08

LeMaitre Vascular goes ex dividend tomorrow

Aug 23

LeMaitre Vascular: 16% Return Objective From Idiosyncratic Risk Premia

Jun 24

What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Jun 15

Are Investors Undervaluing LeMaitre Vascular, Inc. (NASDAQ:LMAT) By 40%?

May 06

LeMaitre Vascular: Steady As She Goes

Apr 07

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero LeMaitre Vascular. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:LMAT Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	200	34	75	17
31 Dec 23	193	30	73	17
30 Sep 23	186	27	70	16
30 Jun 23	177	25	68	15
31 Mar 23	169	21	65	14
31 Dec 22	162	21	62	13
30 Sep 22	160	21	60	13
30 Jun 22	160	22	58	13
31 Mar 22	158	27	55	12
31 Dec 21	154	27	53	12
30 Sep 21	152	28	51	11
30 Jun 21	151	29	49	10
31 Mar 21	135	24	46	10
31 Dec 20	129	21	46	10
30 Sep 20	122	19	47	10
30 Jun 20	115	16	48	10
31 Mar 20	119	18	50	10
31 Dec 19	117	18	49	9
30 Sep 19	115	19	48	9
30 Jun 19	111	18	47	9
31 Mar 19	108	23	46	9
31 Dec 18	106	23	45	8
30 Sep 18	103	21	44	7
30 Jun 18	104	22	44	7
31 Mar 18	103	18	43	7
31 Dec 17	101	17	43	7
30 Sep 17	98	15	43	7
30 Jun 17	96	14	43	6
31 Mar 17	93	12	42	6
31 Dec 16	89	11	40	6
30 Sep 16	86	11	39	6
30 Jun 16	82	9	38	6
31 Mar 16	79	9	37	6
31 Dec 15	78	8	37	5
30 Sep 15	76	7	36	5
30 Jun 15	74	6	36	5
31 Mar 15	73	5	36	4
31 Dec 14	70	4	36	5
30 Sep 14	70	3	36	5
30 Jun 14	67	3	36	5
31 Mar 14	65	2	36	5
31 Dec 13	64	3	35	5
30 Sep 13	61	3	34	5
30 Jun 13	59	3	33	5

Ingresos de calidad: LMAT tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (15.6%) de LMAT son superiores a los del año pasado (12.8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de LMAT han crecido un 6.3% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de LMAT en el último año (45.9%) supera su media de 5 años (6.3% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de LMAT en el último año (45.9%) superó al de la industria Medical Equipment 3.3%.

LeMaitre Vascular Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

LeMaitre Vascular, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

LeMaitre Vascular, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations

LeMaitre Vascular, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Recent updates

First quarter dividend of US$0.16 announced

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear

LeMaitre Vascular, Inc. to Report Q1, 2024 Results on May 02, 2024

LeMaitre Vascular, Inc., Annual General Meeting, Jun 03, 2024

Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?

Now 22% undervalued

Chairman & CEO exercised options to buy US$983k worth of stock.

Now 22% undervalued

Chairman & CEO recently sold US$6.9m worth of stock

Upcoming dividend of US$0.16 per share

Chairman & CEO notifies of intention to sell stock

Fourth quarter dividend increased to US$0.16

Price target increased by 10% to US$71.29

LeMaitre Vascular, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Full year 2023 earnings: EPS exceeds analyst expectations

LeMaitre Vascular, Inc. (NasdaqGM:LMAT) announces an Equity Buyback for $50 million worth of its shares.

LeMaitre Vascular, Inc. to Report Q4, 2023 Results on Feb 27, 2024

What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Chairman & CEO exercised options to buy US$961k worth of stock.

Chairman & CEO recently sold US$2.8m worth of stock

Chairman & CEO notifies of intention to sell stock

Independent Director exercised options to buy US$395k worth of stock.

Chairman & CEO exercised options to buy US$680k worth of stock.

Upcoming dividend of US$0.14 per share at 1.1% yield

Third quarter 2023 earnings: EPS exceeds analyst expectations

LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on November 30, 2023

Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

LeMaitre Vascular, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment deteriorates as stock falls 18%

Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

Upcoming dividend of US$0.14 per share at 1.0% yield

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2023, Fourth Quarter and Full Year Ending December 31, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

LeMaitre Vascular, Inc. to Report Q2, 2023 Results on Aug 01, 2023

The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Independent Director notifies of intention to sell stock

Chairman & CEO recently sold US$445k worth of stock

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

Chairman & CEO notifies of intention to sell stock

President & Director recently sold US$555k worth of stock

Investor sentiment improves as stock rises 22%

Chairman & CEO notifies of intention to sell stock

Price target increased by 9.0% to US$62.33

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Senior Vice President of Operations notifies of intention to sell stock

President & Director exercised options and sold US$258k worth of stock

Upcoming dividend of US$0.14 per share at 1.1% yield

Full year 2022 earnings released: EPS: US$0.94 (vs US$1.27 in FY 2021)

LeMaitre Vascular, Inc. to Report Q4, 2022 Results on Feb 23, 2023

President & Director exercised options to buy US$145k worth of stock.

Chairman & CEO exercised options to buy US$584k worth of stock.

Chairman & CEO exercised options to buy US$546k worth of stock.

Upcoming dividend of US$0.13 per share

Investor sentiment deteriorated over the past week

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

LeMaitre Vascular, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Lemaitre Vascular, Inc. Appoints Martha Shadan as Director

LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital

LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers

Desglose de ingresos y gastos
Beta